The short answer
Kannengiesser and colleagues reported that the melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine colitis models, published in Inflammatory Bowel Disease in 2008. It is a mouse disease model, and the distance from there to a clinical claim is substantial.
Key facts
- Publication
- Inflamm Bowel Dis, March 2008
- PMID
- 18092346
- Model organism
- Mouse
- Model type
- Induced colitis
- Reported
- Anti-inflammatory potential
- Human trials
- None established
Why colitis models are used
Induced colitis in mice is a standard model for intestinal inflammation, producing measurable tissue damage and inflammatory marker changes on a workable timescale. It is a well-established system with objective endpoints, which makes it a reasonable place to test an anti-inflammatory hypothesis.
What the study reported
Anti-inflammatory potential for KPV in that model. The paper's own language (potential) should be preserved, because it is more careful than the language that usually gets applied to it downstream. A compound showing an effect in an induced disease model has demonstrated something in that model.
Research material referenced
KPV 10mg, third-party HPLC tested
The gap between a model and a condition
Induced colitis in a mouse is not inflammatory bowel disease in a person. The induction is chemical and acute; human IBD is chronic, immunologically complex and heterogeneous. Model systems are chosen because they are tractable, and tractability is bought by simplifying away much of what makes the human condition difficult.
Why the gut was a natural target
Beyond the disease relevance, the intestine is where an orally administered compound would first arrive. The later delivery work, targeting KPV to inflamed intestinal tissue with hyaluronic acid-functionalised carriers, follows directly from this line, and indicates the difficulty was getting enough compound to the right place rather than the compound lacking activity.
What is not claimed
Nothing about inflammatory bowel disease, inflammation or gut health in any person. There is no established human clinical programme for KPV, it holds no marketing authorisation, and material supplied for laboratory research is not related to any therapeutic use.
Frequently asked questions
Has KPV been tested in humans?
No established clinical programme exists. The literature is cell culture and murine models.
Does the colitis result mean it treats IBD?
No. Induced colitis in a mouse is an acute chemical model; human inflammatory bowel disease is chronic and immunologically complex.
Why was the gut studied specifically?
It is both a disease-relevant tissue and where an orally administered compound would first arrive, which is why the later delivery work targets it.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More KPV articles
- KPV in the Published LiteratureAbout 34 indexed records, mostly murine and cell culture. How to search a compound whose abbreviation collides with an unrelated chemical.
- KPV Regulatory StatusNo marketing authorisation anywhere. Why an anti-inflammatory literature makes the claims boundary particularly easy to cross.
- The Transporter That Explains the TripeptideKPV is a substrate for PepT1, the intestinal di- and tripeptide transporter. That single fact organises almost everything published about this molecule.
- Delete the Transporter and the Effect DisappearsIn PepT1 knockout mice, KPV produced none of the effect it produced in wild-type animals. That is a stronger mechanistic test than any dose-response curve.
- When the Tripeptide Is the Address, Not the CargoRecent work increasingly attaches KPV to something else - a dye, a nanoparticle, a drug carrier - and uses its affinity to reach cells overexpressing PepT1.